News Releases

President's Message

President's Message

23/04/2019

SIOPE Newsletter: April 2019 issue

CONECT4CHILDREN (c4c)

CONECT4CHILDREN (c4c)

23/04/2019

As a member for c4c, SIOP Europe shares the goal of improving clinical trial infrastructure to facilitate the development of new drugs for children in Europe.

SIOPE News Roundup

SIOPE News Roundup

23/04/2019

SIOPE News Roundup (February - April 2019)

7th ACCELERATE Paediatric Oncology Conference

7th ACCELERATE Paediatric Oncology Conference

23/04/2019

The 7th edition of the ACCELERATE Paediatric Oncology Conference was successfully held on 14-15 February 2019 in Brussels. Almost 170 delegates from 30 countries worldwide attended the Conference including experts from academia, industry, patient/parent/survivor advocacy groups, foundations and regulatory authorities.

Society Updates

Society Updates

22/04/2019

Professor Pamela Kearns has taken the Presidency of SIOP Europe for the years 2019-2021.

#SIOP Europe2019

#SIOP Europe2019

22/04/2019

All SIOP members have been invited to the first edition of the SIOP Europe 2019 Annual Meeting (20-24 May 2019, Prague, Czech Republic).

#ICCD2019

#ICCD2019

22/04/2019

The International Childhood Cancer Awareness Day(ICCD2019) event was kindly hosted by MEP Elena Gentile (S&D, IT) on 6 March 2019 at the European Parliament.

Joint EFGCP & DIA: Better Medicines for Children Conference

Joint EFGCP & DIA: Better Medicines for Children Conference

22/04/2019

The joint annual EFGCP-DIA Conference took place on the 25-26 October 2018 in Brussels. The aim: taking stock of the progress achieved in the paediatric field after 10 years of the Paediatric Regulation and to discuss what could be done to optimise access to new medicines.

PARTNER Project

PARTNER Project

22/04/2019

PARTNER (ERN-PAEDCAN Partner: Paediatric Rare Tumours Network – PARTNER) is a three year 3rd Health Programme funded project running from January 2018 to December 2020.  The project is a collaboration

QUARTET

QUARTET

22/04/2019

The QUARTET (Excellence in Radiotherapy for Children and Adolescents) Group is finalising the preparations in anticipation of two trials, HR-NBL-2 (High Risk Neuroblastoma) and FaR-RMS (Rhadomyosarcoma).